A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm

🔗 Access full article via ACS Cancer

Anti-HER2 antibody-drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2-low breast cancer . The treatment algorithm for hormone receptor–positive and triple-negative BC needs to be reconsidered .